Fluxion Biosciences, a San Francisco-based provider of cellular analysis tools for use in critical life science, has formed a collaboration with the Stanford University School of Medicine to develop tests to help deliver more effective therapies to cancer patients.
The collaboration will focus on breast and lung cancer pathologies. The research is designed to help subtype different forms of the disease and develop more effective treatments tailored to each patient.
Dr. Stefanie Jeffrey’s laboratory at Stanford will be utilizing Fluxion’s IsoFlux System to isolate, recover and analyze rare circulating cancer cells at the molecular level. The IsoFlux System utilizes a proprietary microfluidic technology to isolate rare cells with high efficiency. Samples coming from the IsoFlux System are immediately ready for downstream analysis. A variety of analytical techniques are available for isolated cell samples such as mutation detection, gene expression, sequencing, and protein analysis.
“We are very excited to be working with Dr. Jeffrey on this project,” said Michael Schwartz, program director at Fluxion. “She is widely respected as a leader in the field of personalized cancer therapies, and is backed by the support of a world-class medical institution at Stanford.”